Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $27.9 million.

  • Ligand Pharmaceuticals' Accumulated Expenses rose 54.38% to $24.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.1 million, marking a year-over-year increase of 54.38%. This contributed to the annual value of $27.9 million for FY2024, which is 123.84% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Accumulated Expenses stood at $27.9 million for FY2024, which was up 123.84% from $12.5 million recorded in FY2023.
  • Ligand Pharmaceuticals' Accumulated Expenses' 5-year high stood at $27.9 million during FY2024, with a 5-year trough of $12.5 million in FY2023.
  • Over the past 3 years, Ligand Pharmaceuticals' median Accumulated Expenses value was $15.7 million (recorded in 2022), while the average stood at $18.7 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Accumulated Expenses declined by 20.50% in 2023, and later surged by 123.84% in 2024.
  • Yearly analysis of 5 years shows Ligand Pharmaceuticals' Accumulated Expenses stood at $18.5 million in 2020, then decreased by 5.13% to $17.6 million in 2021, then dropped by 10.80% to $15.7 million in 2022, then dropped by 20.50% to $12.5 million in 2023, then surged by 123.84% to $27.9 million in 2024.